Prostate Cancer Recurrent Clinical Trial
Official title:
Safety and Efficacy of Salvage Lymph Node Dissection in Prostate Cancer Patients With Nodal Recurrence After Radical Prostatectomy With Curative Intent - a Prospective Single Center Phase I/II Study
Despite continuous technical improvements in urologic surgery, up to 40% of prostate cancer patients will develop biochemical recurrence after radical prostatectomy (RP), potentially because of micro metastasis at the time of the primary surgery. With improved radiological modalities and nuclear medicine tracers like 68Ga-PSMA PET/CT, which allow the localization of the site of recurrence, there is increasing interest in metastasis directed therapies, such as salvage lymph node dissection. The pelvic extended salvage lymph node dissection (sLND) is a promising option for treating prostate cancer patients with local recurrence after radical prostatectomy with curative intent. Several retrospective series has been published to determine the local value of sLND. Despite the first data seem to be feasible and promising, to date no prospective evaluation has been made. Thus sLND is still experimental according to the guidelines and is considered as an off label therapy. This prospective single center phase I/II study was conducted to investigate the safety and early efficacy of salvage lymph node dissection in prostate cancer patients with local pelvic recurrence after radical prostatectomy (RP) with curative intention.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT05848011 -
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02562131 -
PET-MR-PSA Prostate Cancer Recidive Study
|
||
| Completed |
NCT04134130 -
The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer
|
N/A | |
| Recruiting |
NCT03507595 -
Evaluation of the Metastasis and Recurrence of Prostate Cancer
|
||
| Active, not recruiting |
NCT04983628 -
Molecular Profiling in Prostate Cancer
|
||
| Completed |
NCT03739684 -
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT04686188 -
Exploring the Mechanisms and Dynamics of Clonal Evolution Leading to Recurrence in Prostate Cancer
|
||
| Active, not recruiting |
NCT04114825 -
Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05646550 -
Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT04876755 -
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT01938339 -
Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer
|
N/A | |
| Completed |
NCT01857037 -
Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI
|
N/A | |
| Active, not recruiting |
NCT03444844 -
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04102553 -
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
|
Phase 3 | |
| Completed |
NCT03443609 -
Study of 68Ga-HBED-PSMA PET/CT and Conventional Imaging in Occult Biological Relapse Prostate Cancer
|
N/A | |
| Recruiting |
NCT05036226 -
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT04324983 -
Identification of Predictive Biomarkers
|
N/A | |
| Completed |
NCT02176161 -
Metformin Prostate Cancer Adjuvant Trial
|
Phase 2 | |
| Active, not recruiting |
NCT04734184 -
A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
|
Phase 3 |